Gaucher Disease

Name
Gaucher Disease
Accession Number
DBCAT000146
Description
Not Available
Drugs
DrugDrug Description
ImigluceraseA form of recombinant human beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease.
AlgluceraseA form of recombinant beta-glucocerebrosidase enzyme used to replace the deficient endogenous enzyme in the treatment of Gaucher disease.
MiglustatA glucosylceramide synthase inhibitor used for the management of mild to moderate type I Gaucher disease for patients who are not candidates for whole enzyme replacement.
Taliglucerase alfaA hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease.
EliglustatA glucosylceramide synthase used to treat type 1 Gaucher disease in patients who are CYP2D6 extensive, intermediate, or poor metabolizers, based on the FDA-approved test.
Drugs & Drug Targets
DrugTargetType
ImigluceraseGlucocerebrosidetarget
AlgluceraseGlucocerebrosidetarget
MiglustatCeramide glucosyltransferasetarget
Taliglucerase alfaGlucocerebrosidetarget
EliglustatCeramide glucosyltransferasetarget
EliglustatCytochrome P450 2D6enzyme
EliglustatCytochrome P450 3A4enzyme
EliglustatP-glycoprotein 1transporter